Jeff Aycock

6.8k total citations · 1 hit paper
24 papers, 624 citations indexed

About

Jeff Aycock is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Jeff Aycock has authored 24 papers receiving a total of 624 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Immunology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Jeff Aycock's work include CAR-T cell therapy research (23 papers), Biosimilars and Bioanalytical Methods (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). Jeff Aycock is often cited by papers focused on CAR-T cell therapy research (23 papers), Biosimilars and Bioanalytical Methods (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). Jeff Aycock collaborates with scholars based in United States, Germany and Netherlands. Jeff Aycock's co-authors include Frederick L. Locke, Yizhou Jiang, Tanya Siddiqi, John M. Rossi, Adrian Bot, William Y. Go, Sattva S. Neelapu, Meg Elias, Nancy L. Bartlett and Jeff Wiezorek and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jeff Aycock

24 papers receiving 613 citations

Hit Papers

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
    2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy profile →

Peers

Jeff Aycock
Comparison fields: 5 of 37
  • Oncology 589
  • Genetics 170
  • Molecular Biology 155
  • Immunology 144
  • Biomedical Engineering 142
Replace Meg Elias with:
Meg Elias United States
Christina A. Bachmeier United States
Birju Mehta United States
Elizabeth Halton United States
Bindu George United States
Barbara Pender United States
Ian R. Hardy United States
Danielle Vanasse United States
Stefanie Lesch Germany
Sharon Yim United States
Meg Elias United States View profile →
Citations per field, relative to Jeff Aycock
Jeff Aycock · 1×
Citations per year, relative to Jeff Aycock
Jeff Aycock · 1×

Countries citing papers authored by Jeff Aycock

Since Specialization
Citations

This map shows the geographic impact of Jeff Aycock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Aycock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Aycock more than expected).

Fields of papers citing papers by Jeff Aycock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Aycock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Aycock. The network helps show where Jeff Aycock may publish in the future.

Co-authorship network of co-authors of Jeff Aycock

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Aycock. A scholar is included among the top collaborators of Jeff Aycock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Aycock. Jeff Aycock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma.
2022 ·Journal of Clinical Oncology ·Brian Gastman, Omid Hamid, Pippa Corrie, Bartosz Chmielowski, Sajeve Thomas, Gregory A. Daniels, Evidio Domingo‐Musibay, Donald P. Lawrence, Eric D. Whitman, Geoffrey T. Gibney, Anthony J. Olszanski, Yizhou Jiang, (unknown), Jeff Aycock, Paul B. Robbins, (unknown), Zachary Roberts, Robert E. Hawkins, Amod A. Sarnaik
2
2
544 DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma
2021 ·SHILAP Revista de lepidopterología ·Brian Gastman, Omid Hamid, Pippa Corrie, Geoffrey T. Gibney, Gregory A. Daniels, Bartosz Chmielowski, Sajeve Thomas, Evidio Domingo‐Musibay, Donald P. Lawrence, Yizhou Jiang, (unknown), Jeff Aycock, (unknown), Paul F. Robbins, (unknown), Zachary Roberts, Robert D. Hawkins, Amod A. Sarnaik
2
3
Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial
2018 ·Biology of Blood and Marrow Transplantation ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, (unknown), Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
1
4
ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
2017 ·Annals of Oncology ·(unknown), Alan S. Wayne, Van Huynh, Rupert Handgretinger, Rob Pieters, (unknown), André Baruchel, Tobias Feuchtinger, Y Bertrand, (unknown), Patrick A. Brown, (unknown), Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Armen Mardiros, Jeffrey S. Wiezorek, Rajul K. Jain
7
5
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma breakdown →
2017 ·Molecular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go
463
6
Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial
2017 ·Annals of Oncology ·Bijal Shah, Wendy Stock, William G. Wierda, Max S. Topp, Marie José Kersten, Roch Houot, Nicolas Boissel, Holly E. Holmes, Gary J. Schiller, Armen Mardiros, (unknown), Yizhou Jiang, Tong Shen, Jeff Aycock, (unknown), Jeff Wiezorek, Rajul K. Jain
1
7
Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL).
2017 ·Journal of Clinical Oncology ·Frederick L. Locke, Jason R. Westin, David B. Miklos, Alex F. Herrera, Caron A. Jacobson, Lillian Lee, John M. Rossi, Adrian Bot, Allen Xue, Lynn Navale, Jeff Aycock, Jeffrey S. Wiezorek, Zachary Roberts
9
8
Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
2017 ·Journal of Clinical Oncology ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeffrey S. Wiezorek, William Y. Go
24
9
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
2017 ·Journal of Clinical Oncology ·Bijal Shah, William G. Wierda, Gary J. Schiller, Michael R. Bishop, Januario E. Castro, Marianna Sabatino, Adrian Bot, Armen Mardiros, John M. Rossi, Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Jeffrey S. Wiezorek, Rajul K. Jain
10
10
KTE-C19, an Anti-CD19 Chimeric Antigen an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions
2017 ·Clinical Lymphoma Myeloma & Leukemia ·Bijal Shah, Wendy Stock, William G. Wierda, Max S. Topp, Marie José Kersten, Roch Houot, Nicolas Boissel, Houston Holmes, Gary J. Schiller, Armen Mardiros, John M. Rossi, Yizhou Jiang, Tong Shen, Jeff Aycock, (unknown), Jeff Wiezorek, Rajul K. Jain
1
11
KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4
2017 ·Clinical Lymphoma Myeloma & Leukemia ·Daniel W. Lee, Alan S. Wayne, Van Huynh, Rupert Handgretinger, Rob Pieters, Gérard Michel, André Baruchel, Tobias Feuchtinger, Yves Bertrand, (unknown), Patrick A. Brown, John M. Rossi, Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Armen Mardiros, Jeff Wiezorek, Rajul K. Jain
1
12
Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
2017 ·Cancer Research ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Jonathan W. Friedberg, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
15
13
A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1
2016 ·Blood ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Caron A. Jacobson, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Alex F. Herrera, Ann S. LaCasce, Adrian Bot, John M. Rossi, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
23
14
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
2016 ·Annals of Oncology ·Bijal Shah, Januario E. Castro, Nicola Gökbuget, Marie José Kersten, (unknown), William G. Wierda, Gary J. Schiller, Adrian Bot, John M. Rossi, Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Jeff Wiezorek, Rajul K. Jain
4
15
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
2016 ·Annals of Oncology ·M. Wang, Frederick L. Locke, Tanya Siddiqi, Januario E. Castro, Bijal Shah, (unknown), Lihua E. Budde, Michael Y. Choi, Claudio Anasetti, Richard E. Champlin, Stephen J. Forman, Thomas J. Kipps, Adrian Bot, John M. Rossi, Lynn Navale, Yanfei Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
7
16
Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)
2016 ·Annals of Oncology ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Amanda F. Cashen, Lihua E. Budde, Marc S. Sherman, (unknown), Lynn Navale, Yuzhang Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
3
17
ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
2016 ·Journal of Clinical Oncology ·Alan S. Wayne, Leonard S. Sender, (unknown), Rupert Handgretinger, Patrick A. Brown, Yizhou Jiang, Lynn Navale, (unknown), Jeff Aycock, Jeffrey S. Wiezorek, Rajul K. Jain
5
18
Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).
2016 ·Journal of Clinical Oncology ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Amanda F. Cashen, Lihua E. Budde, Adrian Bot, (unknown), Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeffrey S. Wiezorek, William Y. Go
3
19
Abstract 2308: Manufacturing and characterization of KTE-C19 in a multicenter trial of subjects with refractory aggressive non-Hodgkin's lymphoma (NHL) (ZUMA-1)
2016 ·Cancer Research ·Marc Better, (unknown), (unknown), (unknown), Jeff Aycock, Emily Lowe, (unknown), Arianne Perez, Lynn Navale, John M. Rossi, Adrian Bot
2
20
Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
2015 ·Blood ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Lynn Navale, Jeff Aycock, Jeff Wiezorek, William Y. Go
7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meg Elias Breakdown of academic impact, for papers by Christina A. Bachmeier Breakdown of academic impact, for papers by Birju Mehta Breakdown of academic impact, for papers by Elizabeth Halton Breakdown of academic impact, for papers by Bindu George Breakdown of academic impact, for papers by Barbara Pender Breakdown of academic impact, for papers by Ian R. Hardy Breakdown of academic impact, for papers by Danielle Vanasse Breakdown of academic impact, for papers by Stefanie Lesch Breakdown of academic impact, for papers by Sharon Yim
Rankless by CCL
2026